• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Angiotech Pharmaceuticals

Angiotech Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Investing
  1. Higher Estate Taxes: Bad Idea

    Recent weakness has increased buying opportunities in the Canadian stock market.

  2. Bat Like Babe Ruth with These Three Small-Cap Stocks

    Would you rather invest in a portfolio in which more than half the stocks go up, or one in which only 40% of the stocks go up? Well, if you chose the former, you wouldn't be alone, but you might not end up any wealthier. The reason you wouldn't be alone is that people want to avoid losses--so much ...

  3. Week in Stocks: A Top Telecom Pick Scores a Big Win

    Plus, Pfizer stubs a toe, DeVry draws undergrads, and more.

  4. Bad Investor Behavior: Overemphasizing Experience

    Abbott Labs ABT had a strong showing at the American College of Cardiology's annual meeting this weekend, but the news was less positive for Boston Scientific BSX and partner Angiotech ANPI . Abbott revealed data from a head-to-head trial that demonstrated its Xience V drug-eluting stent performed ...

  5. Planning for College Costs, Part I

    Angiotech ANPI turned in a messy third quarter Wednesday and reduced its outlook for 2006. However, we still believe in the firm's long-term potential and are sticking to our fair value estimate. The firm now expects sales of about $302-$306 million in 2006, versus the $325-$335 million previously ...

  6. Bat Like Babe Ruth with These Three Small-Cap Stocks

    We've found some picks with home-run potential.

  7. Timely Tax Tips for 2014

    Following is a roundup of stocks that recently jumped to 5 stars. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially compelling ...

©2017 Morningstar Advisor. All right reserved.